 Haleon PLC LSE:HLN, NYSE:HLN shares recouped some of their losses since being spun out of GSK earlier this year as the consumer healthcare group rejected any liability in the Zantac lawsuits that have hit its parent hard. As well as publishing its maiden interim results, including a 13.4 increase in revenues 5.2bn and a 22 jump in profits, the FTSE 100-listed group said it had rejected requests from GSK and Pfizer to provision for costs related to the Zantac lawsuits in the US. 